drugset / Trial / NCT05642780
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Phase 2
Active not recruiting
240 enrolled
Klus Pharma Inc.
Clario · collabDiscovery Life Sciences, LLC · collabFrontage Laboratories, Inc. · collabMyriad Genetics, Inc. · collabVentana Medical Systems, Inc · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of combination of SKB264 and Pembrolizumab in patients with selected solid tumors including cervical cancer, urothelial cancer, ovarian cancer, prostate cancer,advanced endometrial cancer.
Timeline
- Start
- 2023-01-17
- Primary completion
- 2027-11-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Sacituzumab Tirumotecan | Other / unclassified | — | Intravenous |